| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to organic chemistry, namely new oxoazetidine derivatives of general formula n , n as well as to respective salts of a compound of formula (I) with pharmaceutically acceptable acid, and enantiomers of the compound of formula (I), wherein R1 is phenyl; phenyl substituted by 1-2 groups specified in alkyl and halogen; cycloalkyl; R2 is a hydrogen atom; hydroxyl; a linear saturated hydrocarbon chain containing 1 to 6 carbon atoms; cycloalkyl; an oxygen atom attached to a linear saturated hydrocarbon chain containing 1 to 4 carbon and optionally substituted by three halogen atoms; an oxygen atom attached to a linear or branched saturated or unsaturated hydrocarbon chain containing 5 to 10 carbon atoms; R3 is alkyl optionally substituted by hydroxyl or substituted phenyl, which is in turn substituted by one or more groups of atoms specified in halogen, alkoxy and hydroxyl; R4 is heteroaryl, wherein heteroaryl represents imidazole or triazole optionally substituted by one methyl group, and wherein the methyl group is optionally substituted by one hydroxyl group; R5 is a hydrogen atom or hydroxyl. The invention also refers to using the compound of formula (I), pharmaceutical and cosmetic compositions based on the compound of formula (I), cosmetic use of the compositions based on the compound of formula (I). n EFFECT: there are produced new oxoazetidine derivatives able to modulate melanocortin receptors. n 14 cl, 2 tbl, 22 ex |